[Advantages in diagnostic and treatment of MS]

Laeknabladid. 2008 May;94(5):359.
[Article in Icelandic]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Humans
  • Iceland
  • Immunosuppressive Agents / therapeutic use*
  • Multiple Sclerosis / diagnosis*
  • Multiple Sclerosis / drug therapy*
  • Natalizumab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Natalizumab